<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-111815</identifier>
<setSpec>0004-0614</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Cos-benefit of incorporating the detection of circulating prostate cells in a screening programme for prostate cancer</dc:title>
<dc:description xml:lang="en">CONCLUSIONS: The use of primary CPC detection as a complementary test in men with a serum PSA&gt;4.0ng/ml to indicate prostate biopsy is a specific, cost effective test, eliminating approximately 70% of prostate biopsies. This results in a significant health care saving both in direct and indirect costs, in the costs of complications. Implementation costs were minimal as equipment and reagents are part of the routine clinical laboratory. The method deserves further investigation to confirm the results(AU)</dc:description>
<dc:creator>Murray, Nigel P</dc:creator>
<dc:creator>Tapía, Pablo</dc:creator>
<dc:creator>Orellana, Nelson</dc:creator>
<dc:creator>Reyes, Eduardo</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">CONCLUSIÓN: El uso de CPCs como prueba complementaria en pacientes con un PSA elevado es un estudio específico y coste-efectivo que tiene la capacidad de eliminar aproximadamente el 70% de las biopsias de próstata. Esto resulta en un importante ahorro para los sistemas de salud tanto en los costos directos como en los indirectos, en los costes de las complicaciones. Los costos de implementación son mínimos ya que el equipamiento es parte del laboratorio clínico de rutina. Este método merece estudios a mayor escala para confirmar sus resultados(AU)</dc:description>
<dc:source>Arch Esp Urol;66(3): 277-286, abr. 2013. tab</dc:source>
<dc:identifier>ibc-111815</dc:identifier>
<dc:title xml:lang="es">Costo beneficio de la detección de células prostáticas circulantes como test de tamizaje para cáncer de próstata</dc:title>
<dc:subject>^d25123^s22045</dc:subject>
<dc:subject>^d1731^s22074</dc:subject>
<dc:subject>^d11914^s22080</dc:subject>
<dc:subject>^d23568^s22002</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d29310</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d1731^s22018</dc:subject>
<dc:subject>^d11914^s22032</dc:subject>
<dc:subject>^d30313^s22048</dc:subject>
<dc:subject>^d30313^s22049</dc:subject>
<dc:subject>^d11910^s22053</dc:subject>
<dc:subject>^d11910^s22010</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d1731^s22045</dc:subject>
<dc:subject>^d11912^s22018</dc:subject>
<dc:subject>^d25123^s22083</dc:subject>
<dc:subject>^d11914^s22016</dc:subject>
<dc:subject>^d30313^s22074</dc:subject>
<dc:subject>^d28455^s22045</dc:subject>
<dc:type>article</dc:type>
<dc:date>201304</dc:date>
</metadata>
</record>
</ibecs-document>
